Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a ...
SpringWorks Therapeutics is a clinical-stage bi...
Aevi Genomic Medicine is focused on translating genetic discoveries into novel the...
Aevi Genomic Medicine is focused on translating...
Evolus is a performance beauty company with a customer-centric approach focused on...
Evolus is a performance beauty company with a c...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Join the National Investor Network and get the latest information with your interests in mind.